Ling-Hsiang Chuang
Research Subjects
Ling-Hsiang Chuang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ben van Hout
Pharmerit—an OPEN Health Company, 3068 AV Rotterdam, The Netherlands
1 shared publication - Doralisa Morrone
Cardiovascular Division, Pisa University Hospital, 56124 Pisa, Italy
1 shared publication - Fabrizio Ricci
Department of Neuroscience, Imaging and Clinical Sciences, G. D’Annunzio University of Chieti-Pescara , Chieti 66100
1 shared publication - Giulia Renda
Department of Neuroscience, Imaging and Clinical Sciences, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy
1 shared publication - Giuseppe Patti
Department of Thoracic, Heart and Vascular Diseases, Maggiore Della Carità Hospital, Novara, Italy
1 shared publication - Paulus Kirchhof
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
1 shared publication
Latest Publications
- Open Access
- 9 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (12) , 3987
Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation
Background and Objectives: Atrial fibrillation (AF) is associated with increased mortality, predictors of which are poorly characterized. We investigated the predictive power of the commonly used CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75 years, sex category [female]), the HAS-BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol concomitantly), and their combination for mortality in AF patients. Methods: The PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) was a prospective registry including AF patients across seven European countries. We used logistic regression to analyze the relationship between the CHA2DS2-VASc and HAS-BLED scores and outcomes, including mortality, at one year. We evaluated the performance of logistic regression models by discrimination measures (C-index and DeLong test) and calibration measures (Hosmer and Lemeshow goodness-of-fit and integrated discrimination improvement (IDI), with bootstrap techniques for internal validation. Results: In 5209 AF patients with complete information on both scores, average one-year mortality was 3.1%. We found strong gradients between stroke/systemic embolic events (SSE), major bleeding and—specifically—mortality for both CHA2DS2-VASc and HAS-BLED scores, with a similar C-statistic for event prediction. The predictive power of the models with both scores combined, removing overlapping components, was significantly enhanced (p < 0.01) compared to models including either CHA2DS2-VASc or HAS-BLED alone: for mortality, C-statistic: 0.740, compared to 0.707 for CHA2DS2-VASc or 0.646 for HAS-BLED alone. IDI analyses supported the significant improvement for the combined score model compared to separate score models for all outcomes. Conclusions: Both the CHA2DS2-VASc and the HAS-BLED scores predict mortality similarly in patients with AF, and a combination of their components increases prediction significantly. Such combination may be useful for investigational and—possibly—also clinical purposes.
- 9 December 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (12) , 3987
Open AccessMortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation
Background and Objectives: Atrial fibrillation (AF) is associated with increased mortality, predictors of which are poorly characterized. We investigated the predictive power of the commonly used CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75 years, sex category [female]), the HAS-BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol concomitantly), and their combination for mortality in AF patients. Methods: The PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) was a prospective registry including AF patients across seven European countries. We used logistic regression to analyze the relationship between the CHA2DS2-VASc and HAS-BLED scores and outcomes, including mortality, at one year. We evaluated the performance of logistic regression models by discrimination measures (C-index and DeLong test) and calibration measures (Hosmer and Lemeshow goodness-of-fit and integrated discrimination improvement (IDI), with bootstrap techniques for internal validation. Results: In 5209 AF patients with complete information on both scores, average one-year mortality was 3.1%. We found strong gradients between stroke/systemic embolic events (SSE), major bleeding and—specifically—mortality for both CHA2DS2-VASc and HAS-BLED scores, with a similar C-statistic for event prediction. The predictive power of the models with both scores combined, removing overlapping components, was significantly enhanced (p < 0.01) compared to models including either CHA2DS2-VASc or HAS-BLED alone: for mortality, C-statistic: 0.740, compared to 0.707 for CHA2DS2-VASc or 0.646 for HAS-BLED alone. IDI analyses supported the significant improvement for the combined score model compared to separate score models for all outcomes. Conclusions: Both the CHA2DS2-VASc and the HAS-BLED scores predict mortality similarly in patients with AF, and a combination of their components increases prediction significantly. Such combination may be useful for investigational and—possibly—also clinical purposes.
- Open Access
- 30 December 2011
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 101 (1) , 1-15
Mapping for economic evaluation
Mapping provides a statistical algorithm that allows the estimation of utilities and consequently calculation of QALYs in clinical studies where preference-based measures are not implemented. Reviews of the mapping literature were utilized. Mapping requires similar populations between the estimation and study data sets, with a high degree of overlap between the target and base measures being desirable. The National Institute for Health and Clinical Excellence recognizes mapping as a method to provide utility information. Issues surrounding mapping include the descriptive system of the measure, the appropriate econometric method and model specification. There is a need for further research into the issue of over-prediction for severe health states and uncertainty around the estimated utility scores. Mapping continues to be an important area of research for economic evaluation, in particular validation of mapping functions.
- 30 December 2011
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 101 (1) , 1-15
Open AccessMapping for economic evaluation
Mapping provides a statistical algorithm that allows the estimation of utilities and consequently calculation of QALYs in clinical studies where preference-based measures are not implemented. Reviews of the mapping literature were utilized. Mapping requires similar populations between the estimation and study data sets, with a high degree of overlap between the target and base measures being desirable. The National Institute for Health and Clinical Excellence recognizes mapping as a method to provide utility information. Issues surrounding mapping include the descriptive system of the measure, the appropriate econometric method and model specification. There is a need for further research into the issue of over-prediction for severe health states and uncertainty around the estimated utility scores. Mapping continues to be an important area of research for economic evaluation, in particular validation of mapping functions.